Literature DB >> 32958691

Proteome-wide Analysis Reveals Substrates of E3 Ligase RNF146 Targeted for Degradation.

Litong Nie1, Chao Wang1, Nan Li1, Xu Feng1, Namsoo Lee1, Dan Su1, Mengfan Tang1, Fan Yao1, Junjie Chen2.   

Abstract

Specific E3 ligases target tumor suppressors for degradation. Inhibition of such E3 ligases may be an important approach to cancer treatment. RNF146 is a RING domain and PARylation-dependent E3 ligase that functions as an activator of the β-catenin/Wnt and YAP/Hippo pathways by targeting the degradation of several tumor suppressors. Tankyrases 1 and 2 (TNKS1/2) are the only known poly-ADP-ribosyltransferases that require RNF146 to degrade their substrates. However, systematic identification of RNF146 substrates have not yet been performed. To uncover substrates of RNF146 that are targeted for degradation, we generated RNF146 knockout cells and TNKS1/2-double knockout cells and performed proteome profiling with label-free quantification as well as transcriptome analysis. We identified 160 potential substrates of RNF146, which included many known substrates of RNF146 and TNKS1/2 and 122 potential TNKS-independent substrates of RNF146. In addition, we validated OTU domain-containing protein 5 and Protein mono-ADP-ribosyltransferase PARP10 as TNKS1/2-independent substrates of RNF146 and SARDH as a novel substrate of TNKS1/2 and RNF146. Our study is the first proteome-wide analysis of potential RNF146 substrates. Together, these findings not only demonstrate that proteome profiling can be a useful general approach for the systemic identification of substrates of E3 ligases but also reveal new substrates of RNF146, which provides a resource for further functional studies.
© 2020 Nie et al.

Entities:  

Keywords:  E3 ubiquitin ligase; RNF146; TNKS; UbiquitinasesS; cancer biology; label-free quantification; mass spectrometry; protein degradation; substrate identification; substrates; ubiquitin

Year:  2020        PMID: 32958691      PMCID: PMC7710139          DOI: 10.1074/mcp.RA120.002290

Source DB:  PubMed          Journal:  Mol Cell Proteomics        ISSN: 1535-9476            Impact factor:   5.911


  58 in total

Review 1.  Ubiquitin ligases: cell-cycle control and cancer.

Authors:  Keiichi I Nakayama; Keiko Nakayama
Journal:  Nat Rev Cancer       Date:  2006-05       Impact factor: 60.716

2.  Types of Ubiquitin Ligases.

Authors:  Francesca Ester Morreale; Helen Walden
Journal:  Cell       Date:  2016-03-24       Impact factor: 41.582

3.  Engineered diubiquitin synthesis reveals Lys29-isopeptide specificity of an OTU deubiquitinase.

Authors:  Satpal Virdee; Yu Ye; Duy P Nguyen; David Komander; Jason W Chin
Journal:  Nat Chem Biol       Date:  2010-08-29       Impact factor: 15.040

4.  RNF146 is a poly(ADP-ribose)-directed E3 ligase that regulates axin degradation and Wnt signalling.

Authors:  Yue Zhang; Shanming Liu; Craig Mickanin; Yan Feng; Olga Charlat; Gregory A Michaud; Markus Schirle; Xiaoying Shi; Marc Hild; Andreas Bauer; Vic E Myer; Peter M Finan; Jeffery A Porter; Shih-Min A Huang; Feng Cong
Journal:  Nat Cell Biol       Date:  2011-04-10       Impact factor: 28.824

5.  Proteomic Analysis of the Human Tankyrase Protein Interaction Network Reveals Its Role in Pexophagy.

Authors:  Xu Li; Han Han; Mao-Tian Zhou; Bing Yang; Albert Paul Ta; Nan Li; Junjie Chen; Wenqi Wang
Journal:  Cell Rep       Date:  2017-07-18       Impact factor: 9.423

6.  Macrodomain-containing proteins are new mono-ADP-ribosylhydrolases.

Authors:  Florian Rosenthal; Karla L H Feijs; Emilie Frugier; Mario Bonalli; Alexandra H Forst; Ralph Imhof; Hans C Winkler; David Fischer; Amedeo Caflisch; Paul O Hassa; Bernhard Lüscher; Michael O Hottiger
Journal:  Nat Struct Mol Biol       Date:  2013-03-10       Impact factor: 15.369

7.  Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling.

Authors:  Shih-Min A Huang; Yuji M Mishina; Shanming Liu; Atwood Cheung; Frank Stegmeier; Gregory A Michaud; Olga Charlat; Elizabeth Wiellette; Yue Zhang; Stephanie Wiessner; Marc Hild; Xiaoying Shi; Christopher J Wilson; Craig Mickanin; Vic Myer; Aleem Fazal; Ronald Tomlinson; Fabrizio Serluca; Wenlin Shao; Hong Cheng; Michael Shultz; Christina Rau; Markus Schirle; Judith Schlegl; Sonja Ghidelli; Stephen Fawell; Chris Lu; Daniel Curtis; Marc W Kirschner; Christoph Lengauer; Peter M Finan; John A Tallarico; Tewis Bouwmeester; Jeffery A Porter; Andreas Bauer; Feng Cong
Journal:  Nature       Date:  2009-09-16       Impact factor: 49.962

8.  Poly(ADP-ribose)-binding zinc finger motifs in DNA repair/checkpoint proteins.

Authors:  Ivan Ahel; Dragana Ahel; Takahiro Matsusaka; Allison J Clark; Jonathon Pines; Simon J Boulton; Stephen C West
Journal:  Nature       Date:  2008-01-03       Impact factor: 49.962

9.  Tankyrase Inhibitors Target YAP by Stabilizing Angiomotin Family Proteins.

Authors:  Wenqi Wang; Nan Li; Xu Li; My Kim Tran; Xin Han; Junjie Chen
Journal:  Cell Rep       Date:  2015-10-08       Impact factor: 9.423

10.  Metascape provides a biologist-oriented resource for the analysis of systems-level datasets.

Authors:  Yingyao Zhou; Bin Zhou; Lars Pache; Max Chang; Alireza Hadj Khodabakhshi; Olga Tanaseichuk; Christopher Benner; Sumit K Chanda
Journal:  Nat Commun       Date:  2019-04-03       Impact factor: 14.919

View more
  2 in total

1.  Identification of response signatures for tankyrase inhibitor treatment in tumor cell lines.

Authors:  Line Mygland; Shoshy Alam Brinch; Martin Frank Strand; Petter Angell Olsen; Aleksandra Aizenshtadt; Kaja Lund; Nina Therese Solberg; Max Lycke; Tor Espen Thorvaldsen; Sandra Espada; Dorna Misaghian; Christian M Page; Oleg Agafonov; Ståle Nygård; Nai-Wen Chi; Eva Lin; Jenille Tan; Yihong Yu; Mike Costa; Stefan Krauss; Jo Waaler
Journal:  iScience       Date:  2021-07-01

2.  Development of a 1,2,4-Triazole-Based Lead Tankyrase Inhibitor: Part II.

Authors:  Ruben G G Leenders; Shoshy Alam Brinch; Sven T Sowa; Enya Amundsen-Isaksen; Albert Galera-Prat; Sudarshan Murthy; Sjoerd Aertssen; Johannes N Smits; Piotr Nieczypor; Eddy Damen; Anita Wegert; Marc Nazaré; Lari Lehtiö; Jo Waaler; Stefan Krauss
Journal:  J Med Chem       Date:  2021-12-08       Impact factor: 7.446

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.